MARKET

CKDXF

CKDXF

Ceryvyn Therapeutics Ltd
OTCPK
0.820
NaN%
Closed 09:30 07/13 EDT
OPEN
--
PREV CLOSE
0.820
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.820
52 WEEK LOW
0.820
MARKET CAP
1.12B
P/E (TTM)
5.61
1D
5D
1M
3M
1Y
5Y
1D
Ceryvyn Therapeutics Rebrands With New ASX Code and Registered Office
TipRanks · 6d ago
Opthea Shareholders Approve Name Change at Extraordinary Meeting
TipRanks · 07/03 01:37
Opthea Director Jeremy Levin Boosts Stake With New Options and Share Purchase
TipRanks · 06/24 23:27
JAF Capital exits substantial holding in Opthea
TipRanks · 06/22 09:32
Opthea director Katherine Connell increases shareholding with on‑market purchase
TipRanks · 06/19 05:33
BNY Mellon Group Exits Substantial Shareholding in Opthea
TipRanks · 06/17 23:19
Opthea Schedules Online Market Update for Investors
TipRanks · 06/09 00:47
Opthea relaunches on ASX with rare lung disease push for OPT-302
TipRanks · 06/02 23:24
More
About CKDXF
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.

Webull offers Ceryvyn Therapeutics Ltd stock information, including OTCPK: CKDXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CKDXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CKDXF stock methods without spending real money on the virtual paper trading platform.